Sexual Dysfunction and Cardiac Risk (the Second Princeton Consensus Conference) - 21/08/11
, Graham Jackson, MD b, Raymond Rosen, PhD a, Elizabeth Barrett-Connor, MD c, Kevin Billups, MD d, Arthur L. Burnett, MD e, Culley Carson, MD f, Melvin Cheitlin, MD g, Robert Debusk, MD h, Vivian Fonseca, MD i, Peter Ganz, MD j, Irwin Goldstein, MD k, Andre Guay, MD l, Dimitris Hatzichristou, MD m, Judd E. Hollander, MD n, Adolph Hutter, MD o, Stuart Katz, MD p, Robert A. Kloner, MD, PhD q, Murray Mittleman, MD r, Francesco Montorsi, MD s, Piero Montorsi, MD t, Ajay Nehra, MD u, Richard Sadovsky, MD v, Ridwan Shabsigh, MD w
Corresponding author. Tel. 732-235-7685; fax: 732-235-7039.Riassunto |
Recent studies have highlighted the relation between erectile dysfunction (ED) and cardiovascular disease. In particular, the role of endothelial dysfunction and nitric oxide in ED and atherosclerotic disease has been elucidated. Given the large number of men receiving medical treatment for ED, concerns regarding the risk for sexual activity triggering acute cardiovascular events and potential risks of adverse or unanticipated drug interactions need to be addressed. A risk stratification algorithm was developed by the First Princeton Consensus Panel to evaluate the degree of cardiovascular risk associated with sexual activity for men with varying degrees of cardiovascular disease. Patients were assigned to 3 categories: low, intermediate (including those requiring further evaluation), and high risk. This consensus study from the Second Princeton Consensus Conference corroborates and clarifies the algorithm and emphasizes the importance of risk factor evaluation and management for all patients with ED. The panel reviewed recent safety and drug interaction data for 3 phosphodiesterase (PDE)-5 inhibitors (sildenafil, tadalafil, vardenafil), with emphasis on the safety of these agents in men with ED and concomitant cardiovascular disease. Increasing evidence supports the role of lifestyle intervention in ED, specifically weight loss and increased physical activity, particularly in patients with ED and concomitant cardiovascular disease. Special management recommendations for patients taking PDE-5 inhibitors who present at the emergency department and other emergency medical situations are described. Finally, further research on the role of PDE-5 inhibition in treating patients with other medical or cardiovascular disorders is recommended.
Il testo completo di questo articolo è disponibile in PDF.Mappa
| The Second Princeton Consensus Conference was supported by unrestricted educational grants from Pfizer Inc., New York, New York; Lilly/ICOS LLC, Bothell, Washington; Vivus, Palo Alto, California; Solvay, Marietta, Georgia; and Sanofi-Synthelabo, Bridgewater, New Jersey. |
Vol 96 - N° 2
P. 313-321 - luglio 2005 Ritorno al numero
Articolo precedente
- Eulogy for Edward D. Freis, MD*
- Vasilios Papademetriou
- Neurobiology of U-Shaped Characteristic in Major Adverse Cardiac Events
- Ernest H. Friedman
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?